Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 29;9(11):372.
doi: 10.3390/jcdd9110372.

Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity

Xinxin Zhang  1 , Yuxi Sun  2 , Yanli Zhang  1 , Fengqi Fang  3 , Jiwei Liu  3 , Yunlong Xia  1 , Ying Liu  1
Affiliations
Review

Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity

Xinxin Zhang et al. J Cardiovasc Dev Dis. .

Abstract

Cardiotoxicity is one of the major side effects of anti-cancer therapy affecting the overall prognosis of patients and possibly leading to the discontinuation of chemotherapy. Traditional cardiovascular tests such as electrocardiography and transthoracic echocardiography have limited sensitivity and specificity for the early detection of myocardial injury. Cardiovascular imaging generally detects cancer therapy-related cardiac dysfunction (CTRCD) at advanced stages, whereas biomarkers are inexpensive, easily detected, reproducible, and capable of detecting even minimal cardiomyocyte damage or mild hemodynamic fluctuations. The presence of circulating cardiac biomarkers has been investigated as early indicators of cardiotoxicity and predictors of subsequent CTRCD. Currently, the most frequently used cardiac biomarkers are cardiac troponin (cTn) and natriuretic peptides (NPs). This review presents the evidence gathered so far regarding the usefulness and limitations of cardiac biomarkers in the field of cardio-oncology.

Keywords: cardiac biomarker; cardio-oncology; cardiotoxicity; early detection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Management strategies for patients receiving potentially cardiotoxic anti-cancer therapy.
See this image and copyright information in PMC

References

    1. Zamorano J.L., Lancellotti P., Rodriguez Munoz D., Aboyans V., Asteggiano R., Galderisi M., Habib G., Lenihan D.J., Lip G.Y.H., Lyon A.R., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur. Heart J. 2016;37:2768–2801. doi: 10.1093/eurheartj/ehw211. - DOI - PubMed
    1. Lyon A.R., Lopez-Fernandez T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur. Heart J. Cardiovasc. Imaging. 2022;23:e333–e465. doi: 10.1093/ehjci/jeac106. - DOI - PubMed
    1. Ananthan K., Lyon A.R. The Role of Biomarkers in Cardio-Oncology. J. Cardiovasc. Transl. Res. 2020;13:431–450. doi: 10.1007/s12265-020-10042-3. - DOI - PMC - PubMed
    1. Cardinale D., Biasillo G., Salvatici M., Sandri M.T., Cipolla C.M. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert Rev Mol Diagn. 2017;17:245–256. doi: 10.1080/14737159.2017.1283219. - DOI - PubMed
    1. Pudil R., Mueller C., Celutkiene J., Henriksen P.A., Lenihan D., Dent S., Barac A., Stanway S., Moslehi J., Suter T.M., et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur. J. Heart Fail. 2020;22:1966–1983. doi: 10.1002/ejhf.2017. - DOI - PubMed

LinkOut - more resources